↓ Skip to main content

Ebola: translational science considerations

Overview of attention for article published in Journal of Translational Medicine, January 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

1 blog
4 tweeters


44 Dimensions

Readers on

258 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Ebola: translational science considerations
Published in
Journal of Translational Medicine, January 2015
DOI 10.1186/s12967-014-0362-3
Pubmed ID

Francesco Chiappelli, Andre Bakhordarian, April D Thames, Angela M Du, Allison L Jan, Melissa Nahcivan, Mia T Nguyen, Nateli Sama, Ercolano Manfrini, Francesco Piva, Rafael Rocha, Carl A Maida


We are currently in the midst of the most aggressive and fulminating outbreak of Ebola-related disease, commonly referred to as ¿Ebola¿, ever recorded. In less than a year, the Ebola virus (EBOV, Zaire ebolavirus species) has infected over 10,000 people, indiscriminately of gender or age, with a fatality rate of about 50%. Whereas at its onset this Ebola outbreak was limited to three countries in West Africa (Guinea, where it was first reported in late March 2014, Liberia, where it has been most rampant in its capital city, Monrovia and other metropolitan cities, and Sierra Leone), cases were later reported in Nigeria, Mali and Senegal, as well as in Western Europe (i.e., Madrid, Spain) and the US (i.e., Dallas, Texas; New York City) by late October 2014. World and US health agencies declared that the current Ebola virus disease (EVD) outbreak has a strong likelihood of growing exponentially across the world before an effective vaccine, treatment or cure can be developed, tested, validated and distributed widely. In the meantime, the spread of the disease may rapidly evolve from an epidemics to a full-blown pandemic. The scientific and healthcare communities actively research and define an emerging kaleidoscope of knowledge about critical translational research parameters, including the virology of EBOV, the molecular biomarkers of the pathological manifestations of EVD, putative central nervous system involvement in EVD, and the cellular immune surveillance to EBOV, patient-centered anthropological and societal parameters of EVD, as well as translational effectiveness about novel putative patient-targeted vaccine and pharmaceutical interventions, which hold strong promise, if not hope, to curb this and future Ebola outbreaks. This work reviews and discusses the principal known facts about EBOV and EVD, and certain among the most interesting ongoing or future avenues of research in the field, including vaccination programs for the wild animal vectors of the virus and the disease from global translational science perspective.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 258 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 3 1%
Indonesia 1 <1%
Ireland 1 <1%
Sierra Leone 1 <1%
Brazil 1 <1%
Canada 1 <1%
United States 1 <1%
Unknown 249 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 46 18%
Researcher 39 15%
Student > Ph. D. Student 38 15%
Student > Bachelor 33 13%
Student > Postgraduate 21 8%
Other 38 15%
Unknown 43 17%
Readers by discipline Count As %
Medicine and Dentistry 44 17%
Agricultural and Biological Sciences 29 11%
Nursing and Health Professions 27 10%
Social Sciences 22 9%
Biochemistry, Genetics and Molecular Biology 13 5%
Other 68 26%
Unknown 55 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2022.
All research outputs
of 21,619,833 outputs
Outputs from Journal of Translational Medicine
of 3,733 outputs
Outputs of similar age
of 321,543 outputs
Outputs of similar age from Journal of Translational Medicine
of 41 outputs
Altmetric has tracked 21,619,833 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,733 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,543 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.